Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascalle S Monraats

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Disease Markers|May 2, 2009
Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndromeDouwe Pons, Pascalle S Monraats, Aeilko H Zwinderman, et al.
Atherosclerosis|November 8, 2006
The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden miceDaniel Eefting, Abbey Schepers, Margreet R De Vries, et al.
Pharmacogenetics and Genomics|April 13, 2006
Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1Jasper S Wijpkema, Paul L van Haelst, Pascalle S Monraats, et al.
Diabetes Care|March 29, 2005
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary interventionJamal S Rana, Pascalle S Monraats, Aeilko H Zwinderman, et al.
Thrombosis and Haemostasis|March 1, 2005
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placementPascalle S Monraats, Jamal S Rana, Aeilko H Zwinderman, et al.
European Heart Journal|July 3, 2004
Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent eraWillem R P Agema, Pascalle S Monraats, Aeilko H Zwinderman, et al.
Thrombosis and Haemostasis|December 8, 2007
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventionsDouwe Pons, Pascalle S Monraats, Moniek P M de Maat, et al.
Expert Opinion on Therapeutic Targets|January 26, 2010
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary interventionPascalle S Monraats, Yue Fang, Douwe Pons, et al.
Pharmacogenetics and Genomics|September 27, 2006
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary interventionPascalle S Monraats, Florentine de Vries, Laura W de Jong, et al.
Circulation|October 19, 2005
Genetic inflammatory factors predict restenosis after percutaneous coronary interventionsPascalle S Monraats, Nuno M M Pires, Willem R P Agema, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Disease Markers|May 2, 2009
Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndromeDouwe Pons, Pascalle S Monraats, Aeilko H Zwinderman, et al.
Atherosclerosis|November 8, 2006
The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden miceDaniel Eefting, Abbey Schepers, Margreet R De Vries, et al.
Pharmacogenetics and Genomics|April 13, 2006
Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1Jasper S Wijpkema, Paul L van Haelst, Pascalle S Monraats, et al.
Diabetes Care|March 29, 2005
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary interventionJamal S Rana, Pascalle S Monraats, Aeilko H Zwinderman, et al.
Thrombosis and Haemostasis|March 1, 2005
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placementPascalle S Monraats, Jamal S Rana, Aeilko H Zwinderman, et al.
European Heart Journal|July 3, 2004
Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent eraWillem R P Agema, Pascalle S Monraats, Aeilko H Zwinderman, et al.
Thrombosis and Haemostasis|December 8, 2007
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventionsDouwe Pons, Pascalle S Monraats, Moniek P M de Maat, et al.
Expert Opinion on Therapeutic Targets|January 26, 2010
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary interventionPascalle S Monraats, Yue Fang, Douwe Pons, et al.
Pharmacogenetics and Genomics|September 27, 2006
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary interventionPascalle S Monraats, Florentine de Vries, Laura W de Jong, et al.
Circulation|October 19, 2005
Genetic inflammatory factors predict restenosis after percutaneous coronary interventionsPascalle S Monraats, Nuno M M Pires, Willem R P Agema, et al.
Pageof 2